SGI Venture Capital

Founded in 2007, SGI (Samho Green Investment) is the first and only venture capital firm in Korea focused on the green growth sector, including renewable energy, green and agricultural technologies. We engage in venture capital and private equity investments for mergers & acquisitions and buyouts, and conduct business as well as engineering consulting for our portfolio and client companies. Our investment focus areas are green technology (greentech) commercialization, green infrastructure and agricultural technologies (agritech), as well as early-stage project development. We have an experienced team of in-house greentech specialists and an extensive domestic and international greentech network, which assists us in deal sourcing, value creation and exit management.

Jiyoung Tim Kang

Executive Managing Director

30 past transactions

Dime Bio

Series A in 2025
Dime Bio is a drug development company for novel dementia treatments.

Airbility

Seed Round in 2025
Airability is a developer for potential airline mobility solutions.

Soomvi

Venture Round in 2024
Soomvi is a company focused on the industrial drone market, specializing in marine lifesaving systems. The firm develops advanced drones equipped with technology that enables them to recognize and learn from their environment, ensuring enhanced security and operational performance. These drones feature a sensor-isolated and vibration-resistant design, which contributes to their reliability in various applications. Soomvi's drones also offer real-time synchronization and communication capabilities, allowing for effective monitoring of flight information and backup control system operations. This technology positions Soomvi as a key player in providing innovative solutions for industrial needs, particularly in maritime safety.

Lookinsight

Seed Round in 2024
Lookinsight is a solution to solve the problems of the pharmaceutical distribution industry.

Novelty Nobility

Series C in 2024
Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF) and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development.

Unastella

Series A in 2024
Unastella operates its own launch vehicles to provide human space travel platform services.

Vueron

Series A in 2024
Vueron specializes in advanced LiDAR perception software tailored for automotive and industrial applications, aiming to enhance safety through innovative technology. The company develops high-performance, AI-driven algorithms that allow for efficient object detection around LiDAR sensors while utilizing minimal computing resources. Vueron's solutions are designed for immediate integration into advanced driver-assistance systems (ADAS) and autonomous driving technologies, providing critical data on various elements such as lanes, guardrails, and potential obstacles. Additionally, the company offers a software development toolkit for IoT applications, focusing on security and smart city solutions. By collaborating with automotive original equipment manufacturers (OEMs), Tier-1 suppliers, and other industry stakeholders, Vueron delivers practical and cost-effective LiDAR solutions that meet diverse client needs.

PineTree Therapeutics

Series A in 2024
PineTree Therapeutics focuses on creating innovative therapies in the fields of oncology and immuno-oncology. The company is dedicated to addressing unmet medical needs through its advanced biological therapeutics technology. By utilizing platforms that target tumor-associated essential receptors and developing virus-targeting recombinant agents, PineTree Therapeutics aims to enable healthcare professionals to create effective anticancer treatments for patients with solid tumors. Additionally, the company is working on solutions for infectious diseases, further expanding its impact in the medical field.

Gwanak Analog

Series B in 2024
Gwanak Analog is a company specializing in the design and supply of high-performance power and analog system-on-chip (SoC) products. Its offerings cater to various sectors, including industrial, telecommunications, automotive, and consumer applications. By integrating advanced power semiconductor design technology with digital signal processing, Gwanak Analog develops efficient analog and power system semiconductors. This approach helps clients minimize energy consumption in their systems while providing environmentally friendly and compact solutions.

CnerG

Funding Round in 2024
CnerG is a company focused on facilitating clean energy solutions to assist corporations in achieving carbon neutrality and meeting renewable energy targets. The firm operates a cross-border platform for Environmental Commodities, such as Energy Attribute Certificates and Carbon Credits, aimed at global corporations engaged in the voluntary clean energy market. This marketplace streamlines the procurement process for these commodities, offering products from over 80 countries. In addition to the marketplace, CnerG provides a range of software-as-a-service solutions, including contract management, market intelligence, and continuous auditing, all supported by its proprietary blockchain technology, CnerG Chain. This integrated approach enhances operational efficiency and reduces transaction costs for companies navigating power purchase agreements and renewable energy trading.

VEStellaLab

Series B in 2024
VEStellaLab specializes in AI-based navigation services aimed at improving parking experiences for both drivers and autonomous vehicles. Its flagship solution, WatchMile, addresses conventional navigation limitations by providing real-time parking availability and guiding users to optimal parking locations. The technology employs advanced methods such as converting CAD files into lighter digital maps, vision AI recognition, and precise positioning algorithms. This indoor navigation system not only simplifies parking but also alleviates congestion in parking facilities. In addition to WatchMile, VEStellaLab offers Zerocruising, a service tailored for autonomous vehicles, which leverages indoor positioning and vision-AI technologies to enhance parking efficiency. Through these innovative services, VEStellaLab creates significant value in urban transportation and smart city infrastructures.

Chemtopia

Series A in 2023
Chemtopia is a consulting firm that focuses on chemical safety, environmental health, and ESG (Environmental, Social, and Governance) compliance. The company offers a range of services, including environmental testing, risk assessment, product consulting, and chemical substance management. By integrating advanced IT solutions with expertise in environmental consulting, Chemtopia helps businesses adhere to regulatory requirements, manage chemical risks effectively, and pursue sustainability objectives. Utilizing AI and IoT technologies, Chemtopia's smart EHS (Environment, Health, and Safety) platforms aim to enhance workplace safety and improve overall environmental performance for its clients.

VSI

Series B in 2023
VSI specializes in developing semiconductors and networking solutions tailored for the automotive and industrial sectors. The company focuses on automotive networking technologies, producing essential components for next-generation vehicles, including autonomous models. By providing innovative semiconductor products, VSI supports car manufacturers in enhancing vehicle connectivity and functionality.

Tradlinx

Series B in 2022
Tradlinx develops an end-to-end supply chain management platform that enhances global supply chain operations through improved visibility and connectivity. The company's technology offers real-time tracking for bills of lading, vessels, and containers, enabling clients to manage estimated arrival times and delays effectively. Additionally, Tradlinx provides data analytics tools that facilitate data-driven decision-making, optimizing supply chain operations. Recognized as a top freight management solution provider in the Asia Pacific region, Tradlinx aims to create an integrated platform ecosystem that connects all logistics stakeholders. By addressing long-standing market challenges, Tradlinx allows international shippers to access crucial information about global logistics services. The company prioritizes customer feedback to continuously refine its offerings for current and future clients.

PineTree Therapeutics

Series A in 2022
PineTree Therapeutics focuses on creating innovative therapies in the fields of oncology and immuno-oncology. The company is dedicated to addressing unmet medical needs through its advanced biological therapeutics technology. By utilizing platforms that target tumor-associated essential receptors and developing virus-targeting recombinant agents, PineTree Therapeutics aims to enable healthcare professionals to create effective anticancer treatments for patients with solid tumors. Additionally, the company is working on solutions for infectious diseases, further expanding its impact in the medical field.

Novelty Nobility

Series B in 2022
Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF) and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development.

Triz

Series A in 2022
Triz is a commerce platform that specializes in the beauty and healthcare sectors, aiming to create a new ecosystem for commerce and influencers. The company provides a range of services, including commercial management, brand publishing, original equipment manufacturing (OEM), original design manufacturing (ODM), brand distribution, tax assistance, and corporate social responsibility (CSR). By employing a systematic approach, Triz helps businesses maximize sales and achieve sustainable growth in a competitive market.

VEStellaLab

Series A in 2022
VEStellaLab specializes in AI-based navigation services aimed at improving parking experiences for both drivers and autonomous vehicles. Its flagship solution, WatchMile, addresses conventional navigation limitations by providing real-time parking availability and guiding users to optimal parking locations. The technology employs advanced methods such as converting CAD files into lighter digital maps, vision AI recognition, and precise positioning algorithms. This indoor navigation system not only simplifies parking but also alleviates congestion in parking facilities. In addition to WatchMile, VEStellaLab offers Zerocruising, a service tailored for autonomous vehicles, which leverages indoor positioning and vision-AI technologies to enhance parking efficiency. Through these innovative services, VEStellaLab creates significant value in urban transportation and smart city infrastructures.

Angel Robotics

Series B in 2021
Angel Robotics is a company focused on the research, development, manufacturing, and sale of intelligent wearable robotic devices designed to assist individuals with disabilities. Its core products include angel MEDI, a wearable robot tailored for rehabilitation medicine; angel GEAR, an industrial wearable robot; angel SUIT, which aids in daily life activities; and angel KIT, which comprises essential robot components such as motor drivers and smart actuators. The company also engages in research and development for wearable robots intended for defense applications. Through its innovative technology, Angel Robotics aims to enhance the quality of life for users and address various mobility challenges.

Wiju

Series A in 2021
Wiju specializes in integrated marketing solutions aimed at revitalizing traditional and local markets, particularly in Korea. The company has developed a digital marketing platform that focuses on mobile advertising services, allowing businesses to communicate directly with consumers through mobile platforms. By targeting local commercial sectors, Wiju enables its clients to effectively promote their offerings and engage with local consumers, ultimately helping to generate income from these communities. The company's approach supports the growth and sustainability of local markets by enhancing visibility and fostering direct consumer relationships.

Master Meditech

Series A in 2021
Master Meditech Inc., established in 2019 and located in Seoul, South Korea, focuses on the development of new pharmaceuticals through the identification of protein structures and the application of medicinal chemistry. The company aims to innovate drug discovery by leveraging advanced scientific techniques to create effective therapeutic solutions.

Biobab AiBIO

Series A in 2021
Biobab AiBIO is a biotechnology company focused on drug development through the integration of artificial intelligence. It specializes in creating innovative technologies for efficient drug discovery, particularly aimed at addressing intractable and rare diseases. The company has developed bio-space voyager technology that enhances the capabilities of traditional X-ray crystallography by employing cryogenic electron microscopy (cryo-EM). This advanced approach allows for the detailed analysis of the three-dimensional structure of new target proteins, facilitating the identification and development of novel drugs for unique therapeutic targets.

ATsens

Series A in 2021
ATsens operates a healthcare platform focused on enhancing diagnostic capabilities for heart health. The company has developed a small, lightweight, and low-powered patch-type electrocardiograph that allows users to monitor their heart conditions effectively. By providing a comprehensive approach to heart care, ATsens aims to enable individuals to detect potential heart issues with minimal resource consumption, thereby improving overall health management.

PeLeMed

Series A in 2020
PeLeMed is a drug development company focused on creating anti-cancer treatments for patients with incurable cancer and intractable carcinoma. Utilizing a type 1 kinase inhibitor development platform, PeLeMed aims to discover and develop first-in-class therapeutic candidates. This innovative approach not only targets cancer but also seeks to address neurological and immune diseases, with the goal of extending patient survival and improving treatment options.

Macaron M

Series J in 2020
Macaron M is a mobile application that specializes in providing ride-hailing services. The platform allows users to schedule car reservations and choose from a variety of vehicles, all while facilitating a simplified payment process. By offering features such as discounts and the ability to make reservations via phone, Macaron M aims to enhance the travel experience for its customers.

FireVisor

Seed Round in 2019
FireVisor Systems Pte. Ltd., founded in 2018 and based in Singapore, offers an AI-powered software platform that transforms the manufacturing sector by leveraging previously untapped data. The company focuses on automating manufacturing processes to enhance efficiency and quality control. By utilizing artificial intelligence and machine learning, FireVisor's platform detects, analyzes, and monitors defects in production, thereby minimizing the reliance on human inspectors and process control engineers. This innovative approach aims to create self-aware factories that can autonomously optimize operations, reducing costs associated with poor quality and increasing overall profitability for clients. In a global manufacturing industry valued at $17.2 trillion, FireVisor seeks to harness the vast amounts of data generated by machines to drive significant enhancements in productivity and operational effectiveness.

Medi Futures

Venture Round in 2018
Medi Futures is a technology platform specializing in ultrasonic solutions for biomedical companies. The company develops enzyme-free ultrasound stem cell separators and ultrasonic endoscopic disc surgical instruments. Its products aim to enhance surgical outcomes by reducing incision size and procedure duration, while also minimizing patient discomfort. By providing access to advanced ultrasonic and biological fusion medical technologies, Medi Futures supports both cosmetic and surgical applications, ultimately improving the efficiency and effectiveness of medical procedures.

weneepl

Series A in 2018
weneepl is a blockchain game development company.

Insignary

Series A in 2018
Insignary, Inc. is a software company based in Seoul, South Korea, specializing in binary-level software composition analysis. Founded in 2016, the company offers cloud-based solutions that enable comprehensive scanning of open source software binaries to identify and mitigate security vulnerabilities and license compliance issues. Utilizing fingerprint-based technology, Insignary's software eliminates the need for source code or reverse engineering, allowing clients to proactively address potential security threats. The company is supported by venture capital and boasts a team with extensive expertise in IT, particularly in open source software, compliance, and security.

Watcha

Series A in 2013
WATCHA, Inc. is a South Korean company that specializes in online interactive media services, primarily through its movie and TV series recommendation application. Launched in 2012, WATCHA quickly gained popularity in Korea as a leading movie review app, leveraging personalized recommendation technology to suggest films based on user ratings. The platform not only offers extensive movie and TV show reviews but also includes WATCHA PLAY, a subscription-based video-on-demand service launched in 2016. This service is accessible on various devices, including web browsers, mobile applications, and smart TVs. With a strong focus on accurate content recommendations, WATCHA claims that 75% of the content consumed on its platform is based on user-generated recommendations. The company, headquartered in Seoul, has also expanded its offerings to Japan, enhancing its position in the competitive media landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.